Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06744816 · ClinicalTrials.gov registry record · Early Phase 1
Exploring the Benefit of Topical Capsaicin in Treating Pain From Chemo-induced Peripheral Neuropathy: a Longitudinal Single Center Pilot Study
A Early Phase 1 study of Peripheral Neuropathy Due to Chemotherapy, sponsored by M.D. Anderson Cancer Center.
- Recruiting
- Registry status
- Early Phase 1
- Development phase
- 20
- Enrollment target
- 1
- Study location
NCT06744816: Recruiting Early Phase 1 study of Peripheral Neuropathy Due to Chemotherapy, sponsored by M.D. Anderson Cancer Center.
NCT06744816 is a Early Phase 1 study of Peripheral Neuropathy Due to Chemotherapy that is actively recruiting participants, run by M.D. Anderson Cancer Center. The registered enrollment target is 20 participants, below the 58-participant average among 6 other Peripheral Neuropathy Due to Chemotherapy trials with a reported enrollment target (66% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06744816, a Early Phase 1 study of Peripheral Neuropathy Due to Chemotherapy, is actively recruiting participants, sponsored by M.D. Anderson Cancer Center.
- RECRUITING
- Registry status
- Early Phase 1
- Development phase
- 20 participants
- Enrollment target
- 1
- Study location
Study Summary
To learn if topical capsaicin can help relieve pain from CIPN and improve gait (the pattern of walking) in patients.
Primary Outcome
Incidence of Adverse Events, Graded According to National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE) Version (v) 5.0
Conditions Studied
Interventions
- DRUG Qutenza Patch
Study Locations (1)
Texas
- MD Anderson Cancer Center - Houston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 20 participants |
| Start Date | 2025-12-11 |
| Est. Completion | 2027-11-30 |
| Phase | Early Phase 1 |
What NCT06744816 shows while recruiting
NCT06744816 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 20 participants, a relatively small participant target, below the 58-participant average among 6 other Peripheral Neuropathy Due to Chemotherapy trials with a reported enrollment target (66% lower).
The record links to 1 condition, with Peripheral Neuropathy Due to Chemotherapy appearing as the primary indexed condition, and to 1 intervention - of which Qutenza Patch is the first listed.
NCT06744816 reports a single indexed study location in Texas.
Frequently Asked Questions
What is clinical trial NCT06744816 about?
NCT06744816 is a clinical study titled "Exploring the Benefit of Topical Capsaicin in Treating Pain From Chemo-induced Peripheral Neuropathy: a Longitudinal Single Center Pilot Study". To learn if topical capsaicin can help relieve pain from CIPN and improve gait (the pattern of walking) in patients.
What is the current status of trial NCT06744816?
This trial is currently recruiting. It is a Early Phase 1 study. The enrollment target is 20 participants. The study started on 2025-12-11. Estimated completion is 2027-11-30.
What conditions does trial NCT06744816 study?
This clinical trial studies the following conditions: Peripheral Neuropathy Due to Chemotherapy.
What interventions are being tested in trial NCT06744816?
The interventions under investigation include: Qutenza Patch (DRUG).
Who is sponsoring clinical trial NCT06744816?
This trial is sponsored by M.D. Anderson Cancer Center, which has 2,692 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06744816 being conducted?
This trial has 1 study location across Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Peripheral Neuropathy Due to Chemotherapy
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Neuroprotective Potential of Cannabidiol (CBD) in Preventing Oxaliplatin (Ox)-Induced Neuropathy
RECRUITING · Early Phase 1
-
Balance4Mobility: Effects of Walkasins Use in Individuals With Peripheral Neuropathy and Balance Problems
RECRUITING · NA
-
Feasibility Testing of a Tai Chi Program for Chemotherapy-Induced Peripheral Neuropathy Treatment (TCT)
RECRUITING · NA
-
Patient-identified Values as Outcome Targets (PIVOT) Feasibility Pilot Trial
RECRUITING · NA
-
Fall Risk and Quality of Life: in Individuals With Cancer Treatment Related Peripheral Neuropathy.
RECRUITING
-
Closed Loop Spinal Cord Stimulation for Chemotherapy Induced Peripheral Neuropathy, a Pilot Study.
RECRUITING · NA
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00573339 · 20 participants
Cardiac Magnetic Resonance Imaging (MRI) Normal Reference Control Group Testing
- NCT00692939 · 20 participants · Phase 1
Autologous Stem Cell Transplantation for Crohn's Disease
- NCT00967785 · 20 participants · Phase 1
A Phase I Study of Mozobil in the Treatment of Patients With WHIMS
- NCT01406691 · 20 participants · Phase 4
Light Flashes to Treat Delayed Sleep Phase Disorder (DSPD)
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI